On October 16, 2025, CanSino Biologics Inc. (“CanSinoBIO”) convened its 2025 Annual Scientific Advisory Board (SAB) Meeting in Tianjin. The meeting focused on the latest progress across the company’s key R&D pipeline and featured in-depth discussions on vaccine design, clinical strategies, and regulatory requirements in different countries, further reinforcing the strategic direction of advancing global public health through scientific innovation.

Dr. George Siber, Chair of the SAB, together with members Dr. Luis Barreto, Professor Pierre Van Damme, Professor David Salisbury, and Dr. Jingren Zhang, attended the meeting. Dr. Xuefeng Yu, Chairman and CEO of CanSinoBIO, and Dr. Shoubai CHAO, Chief Operating Officer, joined remotely. Dr. Tao ZHU, Chief Scientific Officer; Ms. Jeanne WANG, Chief Commercial Officer, Dr. Qiu Dongxu, Executive Vice President and several project leaders attended in person. The meeting was co-chaired by Dr. Luis Barreto and Dr. Jean Denis Shu, Senior Vice President of Medical Affairs and Pharmacovigilance.

In his remarks, Dr. Yu highlighted the critical role of the SAB Annual Meeting in guiding the company’s R&D strategy and product development roadmap. Over the past year, CanSinoBIO has made significant progress across multiple innovative vaccine programs. Looking ahead, the company will continue to strengthen international scientific collaboration and enhance its R&D capabilities to address shared global health challenges through scientific insight and innovation. Over the years, SAB experts have provided invaluable support for CanSinoBIO’s pipeline planning, product development, and strategic decision-making through their profound academic expertise and global perspectives.

This year’s meeting reviewed progress and future plans for several key vaccine projects, including the tuberculosis vaccine, pneumococcal vaccine, pediatric DTcP vaccine, adolescent and adult Tdcp vaccine, along with the mRNA technology platform. Participants engaged in in-depth discussions on optimizing immunization schedules, clinical study design, and product development strategies.

During the meeting, SAB experts also toured CanSinoBIO’s R&D laboratories and product exhibition center, gaining a detailed understanding of the company’s latest achievements in research innovation, manufacturing capacity, and commercial supply. The SAB members commended CanSinoBIO’s long-term commitment and tangible achievements in advancing vaccine innovation, improving accessibility, and contributing to global health, while offering forward-looking insights and recommendations.